Pharmacodynamic Evaluation of Extending the Administration Time of Meropenem using a Monte Carlo Simulation
- 1 January 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (1), 461-3
- https://doi.org/10.1128/aac.49.1.461-463.2005
Abstract
A Monte Carlo simulation demonstrated that 1 g of meropenem (MEM) every 8 h (q8h) (3-h infusion) has a higher target attainment rate against Pseudomonas aeruginosa than either 500 mg of MEM q8h (3-h infusion) or 0.5 g of imipenem-cilastatin (I-C) q6h (1-h infusion). For other pathogens, 500 mg of MEM q8h was equivalent or superior to I-C.Keywords
This publication has 7 references indexed in Scilit:
- Prevention of Resistance: A Goal for Dose Selection for Antimicrobial AgentsClinical Infectious Diseases, 2003
- CONTINUOUS BETA-LACTAM ANTIBIOTIC THERAPY IN A DOUBLE-LUNG TRANSPLANTED PATIENT WITH A MULTIDRUG-RESISTANT Pseudomonas aeruginosa INFECTIONTransplantation, 2001
- Continuous infusion versus intermittent administration of meropenem in critically ill patientsJournal of Antimicrobial Chemotherapy, 1999
- The Pharmacodynamics of β‐LactamsClinical Infectious Diseases, 1998
- Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic modelAntimicrobial Agents and Chemotherapy, 1997
- The pharmacokinetics of meropenem.1995
- Multiple-dose pharmacokinetics of imipenem-cilastatinAntimicrobial Agents and Chemotherapy, 1984